An Open-Label, Multicenter Extension Study of Onartuzumab in Patients with Solid Tumors on Study Treatment Previously Enrolled in an F. Hoffmann-La Roche- AND/OR Genentech-Sponsored Study

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222922

Enrollment

Registered

2015-07-28

Start date

2015-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

investigational material(s) Generic name etc : Onartuzumab (RO5490258) INN of investigational material : Onartuzumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Signed E-trial Informed Consent Form. - Enrolled and receiving either control treatment or onartuzumab-based study treatment in an eligible P-trial. - Has not met the treatment discontinuation criteria specified in their P-trial protocol at the time of enrollment into the E-trial.

Exclusion criteria

Exclusion criteria: - Pregnancy or lactation or intention to become pregnant during the study. - Any non-protocol anti-cancer therapy started between discontinuation from treatment in P-trial and start of enrollment in E-trial.

Design outcomes

Primary

Measure	Time frame
Safty Serious adverse events considered related to onartuzumab	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026